The automated blister epidermal micrograft (ABEM) is a newly introduced surgical transplantation for refractory vitiligo. Comparative analysis of other surgical methods is lacking. We conducted a retrospective study to compare the efficacy, safety, and experience of ABEM with conventional suction blister epidermal graft (SBEG). A total of 118 anatomically based vitiligo lesions from 75 patients were included. The primary outcome was the degree of repigmentation; the patient and operator experience were evaluated. SBEG had a significantly greater incidence of repigmentation (p < 0.001), as measured by the Physician Global Assessment, as well as improvements in the Vitiligo Area Scoring Index, particularly on the face/neck area (p < 0.001). ABEM, on the contrary, had reduced donor harvest time, a better patient operative experience, and more significant Dermatology Life Quality Index improvements. In a subgroup of 38 lesions from ten patients who received both SBEG and ABEM concomitantly, there was no difference in the degree of repigmentation in the same recipient area. Overall, the degree of repigmentation for SBEG is higher than ABEM, especially in the mobilized region, and the cost is less expensive. On the contrary, ABEM requires less procedure learning curve and can supply a greater transplanting zone with shorter donor site recovery. Understanding the benefits and drawbacks of two blister grafting procedures is essential for optimal surgical outcomes for vitiligo grafting.
A 6-month-old, full-term infant girl was brought to the emergency department after 3 days of having an asymptomatic, large, purple-red bruiselike rash (Figure 1). The rash first appeared on the patient's thighs bilaterally before spreading rapidly to her face, abdomen and lower legs. She had an episode of acute viral gastroenteritis that had resolved 1 week earlier, but she was otherwise healthy. An examination of her skin showed medallionlike, welldefined ecchymoses (2-3 cm in diameter) with surrounding erythematous edematous plaques affecting the face, periumbilical area and extremities (Figure 1); the lesions were warm to the touch. The patient had edema but no fever.Results from laboratory tests showed hypocomplementemia. A biopsy of the patient's skin found perivascular infiltrate with numerous neutrophils, some eosinophils, nuclear dust, abundant extravasated erythrocytes and hemorrhage (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/ cmaj.200418/tab-related-content). Direct immunofluorescence was negative for immunoglobulin deposition. The pathology was compatible with leukocytoclastic vasculitis. We diagnosed acute hemorrhagic edema of infancy. The patient's skin lesions improved spontaneously without specific treatment over a 2-week period.Acute hemorrhagic edema of infancy is an uncommon disorder with a reported incidence of 0.7 cases per 1000 admissions in one case series, mainly affecting infants and children under 2 years of age. 1,2 Although the cause is unclear, the disease may be preceded by infections (e.g., upper respiratory infection or gastroenteritis), medications (e.g., acetaminophen or penicillin) and immunization; an immune complex-mediated pathogenesis has been hypothesized. [1][2][3] The classic clinical triad includes fever, edema and round, palpable, purpuric plaques on the face and extremities. 2 Leukocytosis and hypocomplementemia may be found on examination of the blood, with hematuria and proteinuria noted on urinalysis. 1,4 A skin biopsy showing leukocytoclastic vasculitis is diagnostic. [1][2][3] The differential diagnosis of acute hemorrhagic edema of infancy includes Henoch-Schönlein purpura, urticaria and erythema multiforme. [1][2][3] Acute hemorrhagic edema of infancy may be mistaken for lesions associated with child abuse; thorough screening with prompt reporting as per relevant protocols must be conducted if there is any concern. 3 The disease generally resolves without treatment within 1-3 weeks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.